Sugi Predict

Sugi Predict / Compounds / SCHEMBL119535

SCHEMBL119535

SCHEMBL119535

O=C(N[C@@H]1CCCC[C@H]1C(=O)O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.50
▸ EPHX2 P34913 1/20 0.47
▸ FABP5 Q01469 3/20 0.46
▸ FABP7 O15540 2/20 0.46
▸ CTSB P07858 2/20 0.43
▸ CTSS P25774 2/20 0.43
▸ CTSK P43235 2/20 0.43
▸ CTSL P07711 1/20 0.43
▸ CASP3 P42574 4/20 0.43
▸ MDM4 O15151 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6383724 1.00 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL30055254 1.00 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL2384012 1.00 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL119551 1.00 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL800127 1.00 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL762530 0.97 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL2568254 0.97 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL30054858 0.97 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL20042065 0.97 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB
SCHEMBL33377974 0.97 KMT2A (0.50) KMT2AEPHX2FABP5FABP7CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2024-11-14 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
US-20230080520-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2023-03-16 — — US disclosed
WO-2022234852-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2022-11-10 — — WO disclosed
EP-1229046-A2 Human testis expressed patched like protein Aeomica, Inc. (US) 2002-08-07 — — EP disclosed
EP-1229132-A2 Human ralgds-like protein 3 Aeomica, Inc. (US) 2002-08-07 — — EP disclosed
US-20020102252-A1 Novel isoforms of human pregnancy-associated protein-E AMERSHAM PLC (GB) 2002-08-01 — — US disclosed
EP-1227156-A2 A human protein kinase domain-containing protein Aeomica, Inc. (US) 2002-07-31 — — EP disclosed
US-20020048763-A1 Human genome-derived single exon nucleic acid probes useful for gene expression analysis AMERSHAM PLC (GB) 2002-04-25 — — US disclosed
US-20020048800-A1 Myosin-like gene expressed in human heart and muscle GE HEALTHCARE LIMITED (GB) 2002-04-25 — — US disclosed
WO-2002026818-A2 HUMAN NEDD-1 AEOMICA, INT. (US) 2002-04-04 — — WO disclosed
WO-2002024750-A2 HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 AEOMICA, INC. (US) 2002-03-28 — — WO disclosed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 — — US disclosed
WO-2001092524-A2 MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE AEOMICA, INC. (US) 2001-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS KMT2A 3145/4885EPHX2 3594/4885FABP5 4094/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS KMT2A 3145/4885EPHX2 3594/4885FABP5 4094/4885
US-20230080520-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME APLNR, SCTR, GIPR KMT2A 4557/4885EPHX2 3788/4885FABP5 941/4885
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors CTSK, CTSH, UACA KMT2A 4614/4885EPHX2 3516/4885FABP5 3571/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS KMT2A 4757/4885EPHX2 3088/4885FABP5 4026/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS KMT2A 3145/4885EPHX2 3594/4885FABP5 4094/4885
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME SCTR, GIPR, APLNR KMT2A 4625/4885EPHX2 3499/4885FABP5 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.